L20: Schistosomiasis & Leprosy Flashcards

1
Q

Global Epidemeology of Schistosomiasis

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

National Epidemeology of Schistosomiasis

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Schistosomiasis is endemic in Egypt since …..

A

Ancient Egypt (1250 B.C).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

The prevalence of S. mansoni was ….. and S. haematobium was …… in 1983 before the national control program

A

38.6%, 35%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

In 2014 the prevalence 0f S. mansoni was ….. and S. haematobium was …..

A

0.2%, 0.3%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q
  • S. mansoni is endemic in ….. while
  • S. haematobium is endemic in …..
A

Delta, Upper Egypt

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Epidemic Threshold of Shistosomaisis

A

If the prevalence reaches 3% in a small population or 2% in schools.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Suspected Case of Shistosomaisis

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Probable Case of Shistosomaisis

A

None

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Confirmed Case of Shistosomaisis

A

Presence of Schistosoma eggs in urine and stool

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

CA of Shistosomaisis

A

the major species causing human disease
❢ Schistosoma haematobium
❷ S. manosni
❸ S. Japonicum

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Reservoir of Shistosomaisis

A

Man: Infected persons with S. haematobium or mansoni

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Intermediate Host of Shistosomaisis

A

❢ Bulinus Trancatus: for S.haematobium
❷ Biomphalaria alexandrina: for S.mansoni

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

MOT of Shistosomaisis

A

contact infection (cercaria penetrate bare skin) .

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

IP of Shistosomaisis

A

6-8 weeks

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Infectivity Period of Shistosomaisis

A

No man-to-man transmission but infected person can transmit infection by contaminating water up to 10 years.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Susceptibility & resistance Shistosomaisis

  • Genetic Predisposition
A

❢ HLA class I & II antigens: more severe manifestations of
the disease.

❷ HLA-B16 & Cw2: S. haematobium associated bladder
cancer in Egypt.

❸ HLA-DR, DQ, DP: protection from hepatic fibrosis.

❹ 5q31-q35: Resistance to re-infection.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Susceptibility & resistance Shistosomaisis

  • Age
A

any age is susceptible, the peak at age 15-20y

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Susceptibility & resistance Shistosomaisis

  • Sex
A

more in males: more exposure (working in the field & swimming in canals).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Susceptibility & resistance Shistosomaisis

  • education
A

educated may avoid polluting the environment & exposure to infection.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Susceptibility & resistance Shistosomaisis

  • faculty Habits & Behaviours
A

Pollution of water by passing excreta in water channels.
Exposure to infection by water contact: bathing, ablution,
washing of clothes.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Ecology of Schistosomiasis

(factors favoring endemicity)

  • Host Factors
A

(Previously described under susceptibility & resistance)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Susceptibility & resistance Shistosomaisis

  • Occupation
A

famers, fishermen & workers of water channels clearance

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Ecology of Schistosomiasis

(factors favoring endemicity)

A
  • Host Factors
  • Agent Factors
  • Environmental Factors
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Ecology of Schistosomiasis (factors favoring endemicity) - Agent Factors
26
Ecology of Schistosomiasis (factors favoring endemicity) - Environmental Factors
27
Schistosomiasis may be introduced to the new reclamation areas in Toshki or Sinai through the previous factors .
...
28
General Prevention of **Shistosomaisis** - Environmental Sanitation
29
General Prevention of **Shistosomaisis** - Snail Control
30
Requirements of ideal Molluscicide
31
What is the Name of molluscicide of choice?
Niclosamide
32
General Prevention of **Shistosomaisis** - Health Education
33
General Prevention of **Shistosomaisis** - Protection of Man
Protective clothing unpractical by gloves & boots
34
Specific Prevention of **Shistosomaisis**
Vx: under trial.
35
Case Control Measures for **Shistosomaisis** - Early case Finding
36
Case Control Measures for **Shistosomaisis**
37
Case Control Measures for **Shistosomaisis** - Notification
38
Case Control Measures for **Shistosomaisis** - Isolation
not required
39
Case Control Measures for **Shistosomaisis** - TTT
40
Contact Control Measures for **Shistosomaisis**
Urine and stool analysis.
41
Outbreak (Community) Control Measures for **Shistosomaisis**
Mass treatment if the prevalence reaches the epidemic threshold .
42
Def of **Leprosy [Hansen’s disease]**
- is an infection caused by slow-growing bacteria called Mycobacterium leprae.
43
Previously feared as highly contagious & devastating disease but now we know it doesn’t spread easily and treatment is very effective
.....
44
Global Epidemeology of **Leprosy**
- There were 202,256 new leprosy cases registered globally in 2019, according to official figures from 161 countries from the 6 WHO Regions - The prevalence corresponds to 22.9 per million population
45
National Epidemeology of **Leprosy**
- Since 1994, Egypt has met WHO’s global leprosy elimination goal of reducing prevalence to less than 1 per 10 000 population ## Footnote Study Epidemic Threshold
46
Suspected Case of **Leprosy**
- Person showing one or more of the following features ❢ Hypopigmented or reddish skin lesions with definite loss of sensation ❷ Thickening of the peripheral nerves with loss of sensation
47
CC of **Leprosy**
Skin smear positive for acid-fast bacilli (M Leprae).
48
CA of **Leprosy**
Mycobacterium Leprae (acid fast bacilli)
49
Reservoir of **Leprosy**
Only human
50
Exit of **Leprosy**
Nasal discharge
51
MOT of **Leprosy**
The bacillus is likely transmitted via droplets, from the nose and mouth, during close and frequent contact with untreated cases
52
IP of **Leprosy**
on average, is 5 years. Symptoms may occur within 1 year but can also take as long as 20 years or even more.
53
Types of **Leprosy**
54
Susceptible Age of **Leprosy**
5-15 years is most susceptible
55
Susceptible Families of **Leprosy**
❢ Familial tendency (runs in families but the inheritance pattern is unknown) ❷ Genetic susceptibility
56
General Prevention of **Leprosy**
57
Specific Prevention of **Leprosy**
58
Specific Prevention of **Leprosy** - Active Immunization
❢ BCG vaccine offers a variable amount of protection against leprosy. ❷ Novel vaccine called LepVax entered clinical trials in 2017.
59
Specific Prevention of **Leprosy** - Chemoprophylaxis
Single dose rifampicin for close contact of newly diagnosed patient
60
Case Control measures of **Leprosy**
61
Case Control measures of **Leprosy** - Early Case Finding
the most important measure in control of leprosy
62
Case Control measures of **Leprosy** - Notification
local health office
63
Case Control measures of **Leprosy** - Isolation
no need for isolation, Patients are no longer infectious after the first monthly dose
64
Case Control measures of **Leprosy** - TTT
65
Case Control measures of **Leprosy** - rehab
for patient with deformities and disabilities
66
Contact Control Measures for **Leprosy**
❢ Enlistment by age, sex, vaccination history. ❷ Surveillance for early case finding annually for 5 years . ❸ Specific protection using BCG vaccine and single dose Rifampicin